RxDoctor Payments Data

Joseph Ivey

Urology · Cleveland, TNNPI 1376079269

Payments from drug & device makers

$2,535in general payments, 2019–2025

Across 86 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$225
  • Astellas Pharma US Inc$220
  • Pfizer$216
  • Medtronic$214
  • Johnson & Johnson$214
  • Urogen Pharma, Inc.$198
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,50099%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,535 in reported general payments places this provider in the 40th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$352,163
Medicare patients
418
Services billed
5,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron125$88,996
OrgovyxRelugolix31$80,007
Solifenacin Succinate61$6,842
Estradiol77$5,857
GemtesaVibegron12$5,429
Tamsulosin Hcl413$4,161
Tolterodine Tartrate ErTolterodine Tartrate13$2,193
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst108$1,171
Oxybutynin Chloride ErOxybutynin Chloride77$996
NitrofurantoinNitrofurantoin Macrocrystal22$832
Finasteride60$613
Testosterone Cypionate16$587
CefuroximeCefuroxime Axetil42$430
Doxycycline Hyclate38$336
Cephalexin27$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$220$88,996125 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$225$85,43643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 276 urology providers in Tennessee.

Other urology in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →